185 related articles for article (PubMed ID: 19257897)
1. Addition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis.
Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
BMC Biotechnol; 2009 Mar; 9():15. PubMed ID: 19257897
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of albumin fusion proteins into fibrin clots in vitro and in vivo: comparison of different fusion motifs recognized by factor XIIIa.
Sheffield WP; Eltringham-Smith LJ
BMC Biotechnol; 2011 Dec; 11():127. PubMed ID: 22185689
[TBL] [Abstract][Full Text] [Related]
3. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
Lee KN; Jackson KW; Christiansen VJ; Chung KH; McKee PA
Blood; 2004 May; 103(10):3783-8. PubMed ID: 14751930
[TBL] [Abstract][Full Text] [Related]
4. Characterization of wild-type and mutant alpha2-antiplasmins: fibrinolysis enhancement by reactive site mutant.
Lee KN; Tae WC; Jackson KW; Kwon SH; McKee PA
Blood; 1999 Jul; 94(1):164-71. PubMed ID: 10381509
[TBL] [Abstract][Full Text] [Related]
5. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
6. A novel method to quantify fibrin-fibrin and fibrin-α
Morrow GB; Flannery S; Charles PD; Heilig R; Feller T; McQuilten Z; Wake E; Ariens RAS; Winearls J; Mutch NJ; Fischer R; Laffan MA; Curry N
J Thromb Haemost; 2024 Jun; 22(6):1758-1771. PubMed ID: 38462220
[TBL] [Abstract][Full Text] [Related]
7. Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.
Mosesson MW; Siebenlist KR; Hernandez I; Lee KN; Christiansen VJ; McKee PA
J Thromb Haemost; 2008 Sep; 6(9):1565-70. PubMed ID: 18564219
[TBL] [Abstract][Full Text] [Related]
8. Effect of phenylglyoxal-modified alpha2-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Lee SC; Jackson KW; Tae WC; Schwartzott DG; McKee PA
Thromb Haemost; 1998 Oct; 80(4):637-44. PubMed ID: 9798984
[TBL] [Abstract][Full Text] [Related]
9. The level of circulating fibroblast activation protein correlates with incorporation of alpha-2-antiplasmin into the fibrin clot.
Uitte de Willige S; Malfliet JJCM; Abdul S; Leebeek FWG; Rijken DC
Thromb Res; 2018 Jun; 166():19-21. PubMed ID: 29649768
[TBL] [Abstract][Full Text] [Related]
10. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences.
Abdul S; Leebeek FW; Rijken DC; Uitte de Willige S
Blood; 2016 Feb; 127(5):538-45. PubMed ID: 26626994
[TBL] [Abstract][Full Text] [Related]
11. Alpha2-antiplasmin: potential therapeutic roles in fibrin survival and removal.
Lee KN; Jackson KW; Christiansen VJ; Chung KH; McKee PA
Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):303-10. PubMed ID: 15320781
[TBL] [Abstract][Full Text] [Related]
12. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
Zabczyk M; Natorska J; Bagoly Z; Sarkady F; Barath B; Katona E; Bryk A; Zettl K; Wisniewski JR; Undas A
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214340
[TBL] [Abstract][Full Text] [Related]
13. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism.
Reed GL; Houng AK
Circulation; 1999 Jan; 99(2):299-304. PubMed ID: 9892598
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Fibrinolysis by Coagulation Factor XIII.
Rijken DC; Uitte de Willige S
Biomed Res Int; 2017; 2017():1209676. PubMed ID: 28761875
[TBL] [Abstract][Full Text] [Related]
15. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.
Schneider M; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13333-9. PubMed ID: 14715655
[TBL] [Abstract][Full Text] [Related]
16. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen).
Ritchie H; Lawrie LC; Crombie PW; Mosesson MW; Booth NA
J Biol Chem; 2000 Aug; 275(32):24915-20. PubMed ID: 10816585
[TBL] [Abstract][Full Text] [Related]
17. Thrombomodulin-dependent effect of factor V Leiden mutation on the cross-linking of α2-plasmin inhibitor to fibrin and its consequences on fibrinolysis.
Koncz Z; Bagoly Z; Haramura G; Mezei ZA; Muszbek L
Thromb Res; 2012 Sep; 130(3):528-34. PubMed ID: 22704462
[TBL] [Abstract][Full Text] [Related]
18. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
Mimuro J; Kimura S; Aoki N
J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
[TBL] [Abstract][Full Text] [Related]
19. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Jackson KW; McKee PA
Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
[TBL] [Abstract][Full Text] [Related]
20. Functional factor XIII-A is exposed on the stimulated platelet surface.
Mitchell JL; Lionikiene AS; Fraser SR; Whyte CS; Booth NA; Mutch NJ
Blood; 2014 Dec; 124(26):3982-90. PubMed ID: 25331118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
